Cite

HARVARD Citation

    Freeman, R. et al. (2022). Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages. Annals of clinical and translational neurology. 9 (9), pp. 1370-1383. [Online]. 
  
Back to record